A New-Generation Method for Quick and Owren PT
Juha Horsti1, *, Helena Uppa 1, Juhani A. Vilpo 2
Identifiers and Pagination:Year: 2008
First Page: 81
Last Page: 85
Publisher Id: TOHJ-2-81
Article History:Received Date: 26/04/2008
Revision Received Date: 30/04/2008
Acceptance Date: 02/05/2008
Electronic publication date: 20/5/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Oral anticoagulant therapy (OAT) calls for continuous control by prothrombin time (PT) test, as the therapeutic range in INR units is very narrow. Warfarin (or coumarin) inhibits coagulation factor synthesis in the liver, but at the same time inactive coagulation factors are formed. The aim here was to measure "active coagulation factors" and inhibition in calibrator kits and patient plasmas by a new method for Quick and Owren PT.
Four calibration kits and 200 plasma samples obtained from OAT patients were assessed using Quick and Owren PT for INRTot (active coagulation factors + inhibition) and INRAcf (only active coagulation factors). Conspicuous variation in inhibition was noted between the four calibration kits. The new- generation PT method develops anticoagulation therapy based on active coagulation factors in vivo and improves INR result harmonization for Quick and Owren PT reagents. This new approach improves Quick PT reliability.